Pioglitazone Restores the Homocysteine‑impaired Function of Endothelial Progenitor Cells Via the Inhibition of the Protein Kinase C/NADPH Oxidase Pathway.

Junhui Zhu,Yanbo Zhao,Lu Yu,Meihui Wang,Qinfeng Li,Shengjie Xu
DOI: https://doi.org/10.3892/mmr.2018.9154
IF: 3.423
2018-01-01
Molecular Medicine Reports
Abstract:Homocysteine (Hcy) has been shown to impair the migratory and adhesive activity of endothelial progenitor cells (EPCs). As a peroxisome proliferator-activated receptor agonist, pioglitazone (PIO) has been predicted to regulate angiogenesis, and cell adhesion, migration and survival. The aim of the present study was to determine whether PIO could inhibit Hcy-induced EPC dysfunctions such as impairments of cell migration and adhesion. EPC migration and adhesion were assayed using 8.0-mu m pore size Transwell membranes and fibronectin-coated culture dishes, respectively. Hcy at a concentration of 200 mu M was observed to markedly impair cell migration and adhesiveness, and PIO at a concentration of 10 mu M attenuated the Hcy-mediated inhibition of EPC migration and adhesion. The mechanism of these effects may be through the inhibition of protein kinase C (PKC) and reactive oxygen species production. The expression levels of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase subunits, NADPH oxidase 2 (Nox2) and p67phox, were upregulated by Hcy, with a peak in levels following treatment with a concentration of 200 mu M. PIO downregulated the expression levels of Nox2 and p67phox via the PKC signaling pathway. Furthermore, the mechanism of PIO associated with downregulating the p67phox and Nox2 subunits of NADPH oxidase was verified. Thus, PKC and NADPH oxidase may serve a major role in the protective effects of PIO in EPCs under conditions of high Hcy concentrations.
What problem does this paper attempt to address?